Apolipoprotein A1: A new serum marker correlated to JAK2 V617F proportion at diagnosis in patients with polycythemia vera

作者：Mossuz Pascal^*; Bouamrani Ali; Brugiere Sabine; Arlotto Marie; Hermouet Sylvie; Lippert Eric; Laporte Francois; Girodon Francois; Dobo Irene; Vincent Praloran; Garin Jerome; Cahn Jean Yves; Berger Francois

来源：Proteomics - Clinical Applications, 2007, 1(12): 1605-1612.

DOI：10.1002/prca.200601051

• apolipoprotein-A1
• biomarker
• polycythemia vera
• surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS)

Polycythemia vera (PV) is a myeloproliferative disorder (MPD) characterized by an acquired gain-of-function mutation of the JAK2 protein (JAK2 V617F). Allele-specific quantitative PCR has showed a JAK2 V617F dosage effect on haematological and clinical parameters of PV at diagnosis, but it is unknown whether the level of certain serum proteins might correlate with the proportion of mutated JAK2. Taking into account that such proteins could represent useful prognostic marker, we investigated the serum protein profile of PV patients by SELDI-TOF MS. We identified apolipoprotein A1 (Apo-A1) as a serum marker correlated to the percentage of JAK2 V617F alleles; Apo-A1 expression being the highest for PV patients with more than 75% of mutated alleles. Immuno-assay on an automated random immuno-analyser confirmed the correlation between Apo-A1 concentrations and JAK2 V617F percentages, and showed that serum Apo-A1 assay allowed the specific discrimination of PV patients with high levels of mutated alleles (>= 75%). These data suggest that Apo-A1 assay could be a useful assay for the stratification of PV patients at diagnosis.

• 出版日期2007-12
• 单位中国地震局